Mouse Monoclonal HINT1 Antibody

+ +

•  

   
     All lanes : Anti-HINT1 Antibody at 1:4000 dilution Lane 1: Jurkat whole cell lysates Lane 2: Raji whole cell lysates Lane 3: HepG2 whole cell lysates Lane 4: rat brain lysates Lane 5: mouse liver lysates Lysates/proteins at 20 μg per lane. Secondary Goat Anti-mouse IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution Predicted band size : 14 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized U-2 OS (human bone osteosarcoma cell line) cells labeling HINT1 with P33131 at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-mouse IgG   secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm staining on U-2 OS cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin  at 1/100 dilution (red).The nuclear counter stain is DAPI (blue).    

•  

   
     Overlay histogram showing Jurkat cells stained with P33131 (green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P33131,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Mouse IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(NA168821)) at 1/400 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was mouse IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     P33131 staining HINT1 in human kidney sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

HINT1 (Histidine Triad Nucleotide-Binding Protein 1) is a ubiquitously expressed enzyme belonging to the histidine triad (HIT) superfamily, characterized by a conserved His-X-His-X-His-XX motif involved in nucleotide hydrolysis. Initially identified as a tumor suppressor, HINT1 regulates diverse cellular processes, including transcriptional regulation, apoptosis, and neuromodulation. It interacts with multiple partners, such as protein kinase C (PKC), MITF (microphthalmia-associated transcription factor), and the μ-opioid receptor, modulating signaling pathways and gene expression. HINT1’s role in cancer is context-dependent, with studies showing both tumor-suppressive and oncogenic activities depending on tissue type or interaction partners. For example, HINT1 loss correlates with poor prognosis in certain cancers, while overexpression inhibits tumor growth in others.

HINT1 antibodies are critical tools for studying its expression, localization, and molecular interactions. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess HINT1 levels in cancer tissues, neuronal cells, or drug response studies. Dysregulation of HINT1 is also implicated in neuropsychiatric disorders, including schizophrenia and depression, making its antibodies valuable in neuroscience research. Commercial HINT1 antibodies are typically validated for specificity against human, mouse, or rat isoforms, aiding translational studies. Recent research highlights its potential as a therapeutic target or biomarker, emphasizing the importance of reliable detection reagents. However, users must verify antibody performance due to variability in cross-reactivity or epitope recognition across experimental models.